Thermography Policy
Policy defines coverage stance for thermography (digital infrared thermography and related techniques) for BlueCHiP for Medicare and Commercial products; states thermography is considered not medically necessary due to insufficient evidence and gives billing guidance to report with an unlisted cardiovascular code.
States that all forms of thermography are considered not medically necessary due to insufficient evidence.
Coverage Summary
The policy applies to thermography (digital infrared thermography and related techniques) for BlueCHiP for Medicare and Commercial products. The use of all forms of thermography is considered not medically necessary because evidence is insufficient to determine effects on health outcomes. Evidence supporting this stance includes multiple references and reviews concluding insufficient clinical utility (see references).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.